bioRxivSynthetic BiologyPreprint
Zero-shot antibody design in a 24-well plate
Chai Discovery Team, Jacques BoitreaudiD, Jack Dent, Danny Geisz, Matt McPartloniD, Joshua MeieriD, Zhuoran Qiao, Alex RogozhnikoviD, Nathan Rollins, Paul Wollenhaupt, Kevin WuiD
Abstract
Despite breakthroughs in protein design enabled by artificial intelligence, reliably designing functional antibodies from scratch has remained an elusive challenge. Recent works show promise but still require large-scale experimental screening of thousands to millions of designs to reliably identify hits. In this work, we introduce Chai-2, a multimodal generative model that achieves a 16% hit rate in fully de novo antibody design, representing an over 100-fold improvement compared to previous computational methods. We prompt Chai-2 to design[≤] 20 antibodies or nanobodies to 52 diverse targets, completing the workflow from AI design to wet-lab validation in under two weeks. Crucially, none of these targets have a preexisting antibody or nanobody binder in the Protein Data Bank. Remarkably, in just a single round of experimental testing, we find at least one successful hit for 50% of targets, often with strong affinities and favorable drug-like profiles. Beyond antibody design, Chai-2 achieves a 68% wet-lab success rate in miniprotein design - routinely yielding picomolar binders. The high success rate of Chai-2 enables rapid experimental validation and characterization of novel antibodies in under two weeks, paving the way toward a new era of rapid and precise atomic-level molecular engineering. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=56 SRC="FIGDIR/small/663018v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@69655borg.highwire.dtl.DTLVardef@17d44dborg.highwire.dtl.DTLVardef@133b7ddorg.highwire.dtl.DTLVardef@6c4319_HPS_FORMAT_FIGEXP M_FIG 52 antigens targeted by Chai-2. Blue boxes indicate targets with at least one successful binder out of [≤]20 assayed designs, representing 50% of the tested targets. Date: June 30, 2025 C_FIG
- assay: protein sequence
- research focus: protein design
- research focus: drug response / drug discovery
- research focus: benchmarking
- research focus: software / tool
- approach: deep learning
- Citations
- 45
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Drug-like antibody design against challenging targets with atomic precision
Chai Discovery Team, Jacques Boitreaud, … Andy Yeung·bioRxiv·Nov 29, 2025
- Unlocking de novo antibody design with generative artificial intelligence
Amir Shanehsazzadeh, Matt McPartlon, … Sharrol T. Bachas·bioRxiv·Jan 8, 2023
- Origin-1: a generative AI platform for de novo antibody design against novel epitopes
Simon Levine, Jonathan Edward King, … Amir Shanehsazzadeh·bioRxiv·May 5, 2026
- Rapid De Novo Antibody Design with GeoFlow-V3
BioGeometry Team, Jian Tang·bioRxiv·Oct 20, 2025
- Efficient generation of epitope-targeted de novo antibodies with Germinal
Luis Santiago Mille, Claudia L. Driscoll, … Xiaojing J. Gao·bioRxiv·Sep 19, 2025
- De novo design of epitope-specific antibodies against soluble and multipass membrane proteins with high specificity, developability, and function
Nabla Bio, Surojit Biswas·bioRxiv·Jan 21, 2025